Antitumor effects due to irreversible stoppage of tumor tissue blood flow: Evaluation of a novel combretastatin A-4 derivative, AC7700

Japanese Journal of Cancer Research

Volumn 90, Issue 9, 1999, Pages 1026-1038

  Hori, Katsuyoshi ^a   Saito, Sachiko ^a   Nihei, Yukio ^b   Suzuki, Manabu ^b   Sato, Yasufumi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b AJINOMOTO CO INC   (Japan)

Author keywords

Antivascular; Combretastatin A 4; Solid tumor; Tumor blood flow; Tumor vessel

Indexed keywords

ANTINEOPLASTIC AGENT; COMBRETASTATIN A4; NEW DRUG; PRODRUG; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; UNCLASSIFIED DRUG;

ACUTE DIARRHEA; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; BRAIN BLOOD FLOW; CANCER INHIBITION; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; DOSE RESPONSE; HISTOLOGY; HYDROGEN CLEARANCE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; KIDNEY CORTEX; LIVER BLOOD FLOW; LUNG CARCINOMA; LYMPH NODE METASTASIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS TISSUE TUMOR; TUMOR BLOOD FLOW; TUMOR NECROSIS; WEIGHT REDUCTION; YOSHIDA SARCOMA;

EID: 0032729686     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1999.tb00851.x     Document Type: Article

References (30)

1. Pettit, G. R., Singh, S. B., Hamel, E., Lin, C. M., Alberts, D. S. and Garcia-Kendall, D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia, 45, 209-211 (1989).
2. El-Zayat, A. A. E., Degen, D., Drabek, S., Clark, G. M., Pettit, G. R. and von Hoff, D. D. In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub). Anti-Cancer Drugs, 4, 19-25 (1993).
3. Woods, J. A., Hadfield, J. A., Pettit, G. R., Fox, B. W. and McGown, A. T. The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br. J. Cancer, 71, 705-711 (1995).
4. Pettit, G. R. and Rhodes, M. R. Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug. Anti-Cancer Drug Design, 13, 183-191 (1998).
5. Ohsumi, K., Nakagawa, R., Fukuda, Y., Hatanaka, T., Morinaga, Y., Nihei, Y., Ohishi, K., Suga, Y., Akiyama, Y. and Tsuji, T. Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships. J. Med. Chem., 41, 3022-3032 (1998).
6. Dark, G. G., Hill, S. A., Prise, V. E., Tozer, G. M., Pettit, G. R. and Chaplin, D. J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res., 57, 1829-1834 (1997).
7. Nihei, Y., Suga, Y., Morinaga, Y., Ohishi, K., Suzuki, M., Okano, A., Ohsumi, K., Nakagawa, R., Tsuji, T., Akiyama, Y. and Tsuruo, T. A novel combretastatin A-4 derivative AC7700 shows marked antitumor activity against advanced solid tumors. 89th Annu. Meet. Am. Assoc. Cancer Res., 77 (1998).
8. Hori, K., Suzuki, M., Tanda, S. and Saito, S. In vivo analysis of tumor vascularization in the rat. Jpn. J. Cancer Res., 81, 279-288 (1990).
9. Hori, K., Suzuki, M., Tanda, S., Saito, S., Shinozaki, M. and Zhang, Q.-H. Circadian variation of tumor blood flow in rat subcutaneous tumors and its alteration by angiotensin II-induced hypertension. Cancer Res., 52, 912-916 (1992).
10. Shimosato, Y. and Watanabe, K. Enzymorphological observation on irradiated tumor, with a particular reference to acid hydrolase activity. I. Light microscopic study. Gann, 58, 541-550 (1967).
11. Hori, K., Li, H.-C., Saito, S. and Sato, Y. Increased growth and incidence of lymph node metastases due to the angiogenesis inhibitor AGM-1470. Br. J. Cancer, 75, 1730-1734 (1997).
12. Hori, K., Suzuki, M., Tanda, S., Saito, S., Shinozaki, M. and Zhang, Q.-H. Fluctuations in tumor blood flow under normotension and the effect of angiotensin II-induced hypertension. Jpn. J. Cancer Res., 82, 1309-1316 (1991).
13. Suzuki. M., Hori, K., Saito, S., Tanda, S., Abe, I., Sato, H. and Sato, H. Functional characteristics of tumor vessels: selective increase in tumor blood flow. Sci. Rep. Res. Inst. Tohoku Univ. Ser-C. 36, 37-45 (1989).
14. Hori, K., Zhang, Q.-H., Li, H.-C., Saito, S. and Sato, Y. Timing of cancer chemotherapy based on circadian variations in tumor tissue blood flow. Int. J. Cancer, 65, 360-364 (1996).
15. Hori, K., Saito, S. and Sato, Y. Daily changes in tumor blood flow after cancer chemotherapy. Microcirc. Annu. 1996, 215-216 (1996).
16. Algire, G. H., Legallais, F. Y. and Anderson, B. F. Vascular reaction of normal and malignant tissues in vivo. VI. The role of hypotension in the action of components of podophyllin on transplantable sarcomas. J. Natl. Cancer Inst., 14, 879-893 (1954).
17. Chaplin, D. J. and Acker, B. The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain. Int. J. Radiat. Oncol. Biol. Phys., 13, 579-585 (1987).
18. Hill, S., Williams, K. B. and Denekamp, J. Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action. Eur. J. Cancer Clin. Oncol., 25, 1419-1424 (1989).
19. Hill, S. A., Lonergan, S. J., Denekamp, J. and Chaplin, D. J. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur. J. Cancer, 29A, 1320-1324 (1993).
20. Bibby, M. C., Double, J. A., Loadman, P. M. and Duke, C. V. Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy. J. Natl. Cancer Inst., 81, 216-220 (1989).
21. Zwi, L. J., Baguley, B. C., Gavin, J. B. and Wilson, W. R. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J. Natl. Cancer Inst., 81, 1005-1013 (1989).
22. Baguley, B. C., Holdaway, K. M., Thomsen, L. L., Zhuang, L. and Zwi, L. J. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur. J. Cancer, 27, 482-487 (1991).
23. Horsman, M. R., Christensen, K. L. and Overgaard, J. Relationship between the hydralazine-induced changes in murine tumor blood flow supply and mouse blood pressure. Int. J. Radiat. Oncol. Biol. Phys., 22, 455-458 (1992).
24. Cater, D. B., Grigson, C. M. B. and Watkinson, D. A. Changes of oxygen tension in tumours induced by vasoconstrictor and vasodilator drugs. Acta Radiol., 58, 401-434 (1962).
25. Suzuki, M. Selective increase in intratumoral concentration of anticancer drugs and extension of retention time based on two functional characteristics of tumor vessels. Adv. Cancer Treat., 7, 77-81 (1988) (in Japanese).
26. Krossnes, B. K., Mella, O. and Tyssebotn, I. Effect of sodium nitroprusside-induced hypotension on the blood flow in subcutaneous and intramuscular BT4AN tumors and normal tissues in rats. Int. J. Radiat. Oncol. Biol. Phys., 36, 393-401 (1996).
27. Kallinowski, F., Shaefer, C., Tyler, G. and Vaupel, P. In vivo targets of recombinant human tumour necrosis factor -blood flow, oxygen consumption and growth of isotransplanted rat tumours. Br. J. Cancer, 60, 555-560 (1989).
28. Tozer, G. M., Prise, V. E. and Chaplin, D. J. Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Cancer Res., 57, 948-955 (1997).
29. Iyer, S., Chaplin, D. J., Rosenthal, D. S., Boulares, H., Li, L.-Y. and Smulson, M. E. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific anti-angiogenesis agent combretastatin A-4. Cancer Res., 58, 4510-4514 (1998).
30. Hori, K., Zhang, Q.-H., Saito, S., Tanda, S., Li, H.-C. and Suzuki, M. Microvascular mechanisms of change in tumor blood flow due to angiotensin II, epinephrine, and methoxamine: a functional morphometric study. Cancer Res., 53, 5528-5534 (1993).